Moderna’s ambitions for staying power

Moderna’s hammering in the market this week based on a shifting of a fraction of its COVID-19 sales from 4Q21 to early 2022, drives home the urgency behind the company’s race to find its next products and show it’s not a one-hit wonder.

The biotech’s strategy is to exploit its now-validated mRNA technology across a wide swath of modalities, from the relatively low-hanging fruit of prophylactic vaccines to cancer vaccines and intracellular therapeutics...